Zenas BioPharma, Inc. (ZBIO)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Zenas BioPharma: Obexelimab Is Being Graded On The Wrong Curve
Zenas BioPharma (ZBIO) is advancing obexelimab for IgG4-RD, with FDA acceptance and a May 2027 PDUFA date, positioning as a long-term maintenance therapy. ZBIO maintains a sizable cash runway, with pro forma balances covering operations into late 2028, though financing risk remains if FDA approval is delayed. Obexelimab's non-depleting B cell inhibition offers a differentiated safety profile versus Uplizna, targeting chronic use in older patients and potentially expanding the addressable market.
Zenas BioPharma, Inc. (ZBIO) Discusses Obexelimab Prelaunch Strategy and Commercial Opportunity in IgG4-Related Disease Transcript
Zenas BioPharma, Inc. (ZBIO) Discusses Obexelimab Prelaunch Strategy and Commercial Opportunity in IgG4-Related Disease Transcript
Zenas: 'Strong Buy' On Obexelimab Enhancement And Expected SLE Data Q4 2026
Zenas BioPharma, Inc. maintains a Strong Buy rating, driven by obexelimab's positive phase 3 results in IgG4-RD and regulatory filings planned for 2026. ZBIO is advancing obexelimab into the large SLE market, with phase 2 SunStone topline and biomarker data expected in Q4 2026. Pipeline expansion includes ZB014, a half-life extended anti-CD19/FcγRIIb mAb aiming for once-monthly dosing, and CNS-penetrant BTK inhibitor orelabrutinib in phase 3 for MS.
Zenas BioPharma, Inc. (ZBIO) Discusses Positive Phase 3 INDIGO Trial Results for Obexelimab in IgG4-Related Disease Transcript
Zenas BioPharma, Inc. (ZBIO) Discusses Positive Phase 3 INDIGO Trial Results for Obexelimab in IgG4-Related Disease Transcript
ZBIO Tanks Despite Positive Data From Rare Autoimmune Diseases Study
Zenas BioPharma tanks nearly 52% despite positive INDIGO study data where obexelimab cut IgG4-RD flare risk by 56% and met all key endpoints.
Zenas: Maintaining 'Strong Buy' As Cross-Trial Comparison Of Obexelimab Should Not Be A Factor
Zenas BioPharma remains a 'Strong Buy' after Obexelimab met the phase 3 INDIGO primary endpoint in IgG4-RD, despite a sharp stock decline. The company's pipeline is advancing with Orelabrutinib, a potential best-in-class BTK inhibitor, and multiple phase 3 MS trials underway or planned. Obexelimab offers competitive advantages over UPLINZA, including a differentiated MOA and self-administered SC dosing, targeting elderly IgG4-RD patients.
Zenas BioPharma's immune disorder drug meets main goal in late-stage trial
Zenas BioPharma said on Monday its experimental drug cut the risk of disease flare-ups in a late-stage study of patients with a rare immune system-related condition that can damage organs over time.
Zenas Prepares For INDIGO Phase 3 Readout - Reinstating Buy Rating
Zenas BioPharma is rated a buy ahead of the pivotal INDIGO Phase 3 trial readout for obexelimab in IgG4-RD, expected by year-end. ZBIO's strong balance sheet, with $301.6M in cash and runway into late 2026, supports aggressive late-stage pipeline advancement. Obexelimab's positive Phase 2 MoonStone MS results, showing 95% lesion reduction and clean safety, meaningfully de-risk the company's multi-indication platform.
1 Trial, 2 Franchises: Zenas Stock Climbs on Landmark Data
A pivotal clinical development has sent Zenas BioPharma NASDAQ: ZBIO shares climbing higher, reshaping the company's investment profile overnight. On Oct. 27, 2025, Zenas BioPharma's stock price climbed by over 30% on exceptionally high trading volume, pushing its market capitalization to approximately $1.35 billion and hitting a new 52-week high of over $34.
Zenas BioPharma: Two Late-Stage Catalysts And A $2B InnoCare Deal
Zenas BioPharma (ZBIO) secures a $2B licensing deal with InnoCare, expanding its pipeline with orelabrutinib for global non-oncology indications. ZBIO's two late-stage candidates, obexelimab and orelabrutinib, drive optimism, with topline Phase 3 INDIGO trial data for obexelimab expected in late 2025. Strong cash position and recent private placement provide operational runway through 4Q26, supporting ongoing clinical development and mitigating dilution risks.
Zenas Biopharma: A Risky Buy On Upcoming Data Readouts In IgG4, MS
Zenas BioPharma, Inc.'s Obexelimab offers a differentiated, non-depleting B-cell inhibition approach, with promising Phase 2 data in IgG4 and upcoming pivotal catalysts in 2025. The lead asset's blockbuster potential hinges on positive Phase 3 IgG4 results, with analysts projecting peak sales over $1.5bn if approved. ZBIO risks include obexelimab's prior Phase 2 failure in lupus nephritis and limited pipeline depth, but strong cash reserves support near-term operations.
Zenas: Differentiated B-Cell Targeting Drug With Q3 Of 2025 Catalyst
Dual inhibition of CD19 and FcyRIIb leads to broader B-cell depletion coverage compared to that of other CD19 and CD20 inhibitors. Zenas BioPharma, Inc.'s topline 12-week results, from the phase 2 MoonStone study using obexelimab for the treatment of patients with relapsing multiple sclerosis, are expected in Q3 of 2025. The global relapsing-remitting multiple sclerosis market is expected to reach $5.8 billion by 2032.
